Aspects of hepatitis C virus infection relating to liver transplantation

European Journal of Gastroenterology and Hepatology

Volumn 18, Issue 4, 2006, Pages 313-320

  Roche, Bruno ^a   Samuel, Didier ^a  

^a HÔPITAL PAUL BROUSSE   (France)

Author keywords

Antiviral therapy; Hepatitis C; Liver transplantation

Indexed keywords

ALPHA2B INTERFERON; AMANTADINE; CYCLOSPORIN A; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; INTERFERON; INTERLEUKIN 2 RECEPTOR ANTIBODY; MEPREDNISONE; METHYLPREDNISOLONE SODIUM SUCCINATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RECOMBINANT ERYTHROPOIETIN; RIBAVIRIN; TSUKUBAENOLIDE; VIRUS RNA;

ANEMIA; CLINICAL TRIAL; CONFERENCE PAPER; DEPRESSION; DISEASE COURSE; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; GRAFT INFECTION; GRAFT SURVIVAL; HEMOLYSIS; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOMODULATION; INFECTION; INSOMNIA; IRRITABILITY; KIDNEY FUNCTION; LEUKOPENIA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER DYSFUNCTION; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; NEUTROPENIA; PRIORITY JOURNAL; RECIPIENT; RECURRENT DISEASE; REINFECTION; RETRANSPLANTATION; RISK FACTOR; SEPSIS; SIDE EFFECT; VIRUS LOAD; VIRUS REPLICATION;

ANTIVIRAL AGENTS; GRAFT SURVIVAL; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; RECURRENCE; RIBAVIRIN;

EID: 33645103656     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200604000-00002     Document Type: Conference Paper

References (64)

1. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122:889-896.
2. Berenguer M, Prieto M, San Juan F, Rayon JM, Martinez F, Carrasco D, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36:202-210.
3. Garcia-Retortillo M, Forns X, Folio A, Moitinho E, Costa J, Navasa M, et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002; 35:680-687.
4. Gane E, Naoumov N, Qian K, Mondelli M, Maertens G, Portmann B, et al. A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology 1996; 110:167-177.
5. Gane EJ, Portmann BC, Naoumov NV, Smith H, Underhill J, Donaldson P, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334:815-820.
6. Feray C, Gigou M, Samuel D, Paradis V, Wilber J, David MF, et al. The course of hepatitis C infection after liver transplantation. Hepatology 1994;20:1137-1143.
7. Sreekumar R, Gonzalez-Koch A, Maor-Kendler Y, Batts K, Moreno-Luna L, Poterucha J, et al. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology 2000; 32:1125-1130.
8. Feray C, Caccamo L, Alexander GJM, Ducot B, Gugenheim J, Casanovas T, et al. European collaborative study on factors influencing outcome after liver transplantation for hepatitis C. Gastroenterology 1999; 117:619-625.
9. Prieto M, Berenguer M, Rayon JM, Cordoba J, Arguello L, Carrasco D, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes. Hepatology 1999; 29:250-256.
10. Berenguer M, Prieto M, Rayon JM, Mora J, Pastor M, Ortiz Y, et al. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32:852-858.
11. Charlton M, Seaberg E, Wiesner R, Everhart J, Zetterman R, Lake J, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28:823-830.
12. Berenguer M, Ferrell L, Watson J, Prieto M, Kim M, Rayon M, et al. HCV-related fibrosis progression following liver transplantation increase in recent years. J Hepat 2000; 32:673-684.
13. Neumann UP, Berg T, Bahra M, Seehofer D, Langrehr JM, Neuhaus R, et al. Fibrosis progression after liver transplantation in patients with recurrent hepatitis C. J Hepat 2004; 41:830-836.
14. Rosen HR, Shackleton CR, Higa L, Gralnek I, Farmer D, McDiamid S, et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol 1997; 92:14453-14457.
15. Sheiner PA, Schwartz ME, Mor E, Schluger L, Theise N, Kishikawa K, et al. Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995; 21:30-34.
16. Berenguer M, Prieto M, Cordoba J, Rayon JM, Carrasco J, Olaso V, et al. Early development of chronic active hepatitis in recurrent hepatitis C virus infection after liver transplantation: association with treatment of rejection. J Hepat 1998; 28:756-763.
17. Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002; 51:248-252.
18. Feray C, Gigou M, Samuel D, Paradis V, Mishiro S, Maettens G, et al. Influence of the genotypes of hepatitis C virus on the severity of recurrent liver disease after liver transplantation. Gastroenterology 1995; 108:1088-1096.
19. Russo M, Galanko J, Beavers K, Fired M, Shrestha R. Patient and graft survival in hepatitis C recipients after adult living donor liver transplantation in the United States. Liver Transpl 2004; 10:340-346.
20. Garcia-Retortillo M, Forns X, Llovet JM, Navasa M, Feliu A, Massaguer A, et al. Hepatitis C recurrence is more severe after living donor compared to cadaveric liver transplantation. Hepatology 2004; 40:699-707.
21. Papatheodoridis G, Davies S, Dhillon A, Teixeira R, Goulis J, Davidson B, et al. The role of different immunosuppression in the long-term histological outcome of HCV reinfection after liver transplantation for HCV cirrhosis. Transplantation 2001; 72:412-418.
22. Everson T. Impact of immunosuppressive therapy on recurrence of hepatitis C. Liver Transpl 2002; 8:S19-S27.
23. Feray C, Samuel D, Gigou M, Paradis V, David MF, Lemonnier C, et al. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection. Hepatology 1995; 22:1084-1089.
24. Dousset B, Conti F, Houssin D, Calmus Y. Acute vanishing bile duct syndrome after interferon therapy for recurrent HCV infection in liver-transplant recipients. N Engl J Med 1994; 330:1160-1161.
25. Gaidano AC, Mosnier JF, Durand F. Alpha-interferon-induced rejection of a hepatitis C virus-infected liver allograft tolerated with a low dosage immunosuppressive regimen. Transplantation 1995; 59:1627-1629.
26. Stravitz R, Shiffman M, Sanyal A, Luketic V, Sterling R, Heuman D, et al. Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation. Liver Transpl 2004; 10:850-858.
27. Saab S, Kalmaz D, Gajjar N, Hiatt J, Durazo F, Han S, et al. Outcomes of acute rejection after interferon therapy in liver transplant recipients. Liver Transpl 2004; 10:859-867.
28. Samuel D. Hepatitis C, interferon, and risk of rejection after liver transplantation. Liver Transpl 2004; 10:868-871.
29. Jain A, Eghtesad B, Venkataramanan R, Fontes P, Kashyap R, Dvorchik I, et al. Ribavirin dose modification based on renal function is necessary to reduce hemolysis in liver transplant patients with hepatitis C virus infection. Liver Transpl 2002; 8:1007-1013.
30. Pockros P, Shiffman M, Schiff E, Sulkowski M, Younossi Z, Dieterich D, et al. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology 2004; 40:1050-1058.
31. Afdhal N, Dieterich D, Pockros P, Schiff E, Shiffman M, Sulkowski M, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized, controlled study. Gastroenterology 2004; 126:1302-1311.
32. Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002; 8:350-355.
33. Forns X, Garcia-Retortillo M, Serrano T, Feliu A, Suarez F, de la Mata M, et al. Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepat 2003; 39:389-396.
34. Everson G. Treatment of patients with hepatitis C virus on the waiting list. Liver Transpl 2003; 9:S90-S94.
35. Sheiner PA, Boros P, Klion FM, Thung S, Schluger L, Lau J, et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology 1998; 28:831-838.
36. Singh N, Gayowski T, Wannstedt CF, Shakil A, Wagener M, Fung J, et al. Interferon alfa for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: a prospective, randomized, controlled trial. Transplantation 1998; 65:82-86.
37. Mazzaferro V, Schiavo M, Caccamo L, Tagger A, Morabio A, Lavezzo B, et al. Prospective randomized trial on early treatment of HCV infection after liver transplantation in HCV-RNA positive patients [Abstract]. Liver Transpl 2003; 9:C36.
38. Reddy R, Fried M, Dickson R, Martin P, Schiff E, Torres M, et al. Interferon α-2b and ribavirin vs placebo as early treatment in patients transplanted for hepatitis C end-stage liver disease: results of a multicenter randomized trial [Abstract]. Gastroenterology 2002; 122:199A.
39. Terrault N, Khalili M, Straley S, Bollinger K, Bass N, Roberts J, Ascher N. Efficacy and tolerability of preventive interferon (IFN) versus interferon plus ribavirin (RBV) treatment in hepatitis C virus infected liver transplant recipients [Abstract]. Hepatology 2004; 38:158A.
40. Chalasani N, Manzarbeitia C, Ferenci P, Vogel W, Fontana RJ, Voigt M, et al. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005; 41:289-298.
41. Gane EJ, Lo SK, Riordan SM, Portmann B, Lau J, Naoumov N, et al. A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation. Hepatology 1998; 27:1403-1407.
42. Bizollon T, Palazzo U, Ducerf C, Chevallier M, Elliott M, Baulieux J, et al. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 1997; 26:500-504.
43. Samuel D, Bizollon T, Feray C, Roche B, Ahmed SN, Lemonnier C, et al. Interferon-alfa 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study. Gastroenterology 2003; 124:642-650.
44. Lavezzo B, Franchello A, Smedile A, David E, Barbui A, Torrani M, et al. Treatment of recurrent hepatitis C in liver transplants: efficacy of a six versus a twelve month course of interferon alpha 2b with ribavirin. J Hepat 2002; 37:247-252.
45. De Vera M, Smallwood G, Rosado K, Davis L, Martinez E, Sharma S, et al. Interferon alpha and ribavirin for the treatment of recurrent hepatitis C after liver transplantation. Transplantation 2001; 71:678-686.
46. Alberti A, Belli L, Airoldi A, de Carlis L, Rondinara G, Molina E, et al. Combined therapy with interferon and low-dose ribavirin in posttransplantation recurrent hepatitis C: a pragmatic study. Liver Transpl 2001; 10:870-876.
47. Ahmad J, Dodson SF, Demetris AJ, Fung JJ, Shakil A. Recurrent hepatitis C after liver transplantation: a nonrandomized trial of interferon alpha alone versus interferon alpha and ribavirin. Liver Transpl 2001; 10:863-869.
48. Shakil A, McGuire B, Crippin J, Teperman L, Demetris AJ, Conjeenvaran H, et al. A pilot study of interferon alfa and ribavirin combination in liver transplant recipients with recurrent hepatitis C. Hepatology 2002; 36:1253-1258.
49. Firpi R, Abdelmalek M, Soldevila-pico C, Reed A, Hemming A, Howard R, et al. Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C. Liver Transpl 2002; 8:1000-1006.
50. Narayanan Menon K, Poterucha J, El-Amin O, Burgart L, Kremers W, Rosen C, et al. Treatment of posttransplantation recurrence of hepatitis C with interferon and ribavirin: lessons on tolerability and efficacy. Liver Transpl 2002; 8:623-629.
51. Giostra E, Kullak-Ublick G, Keller W, Fried R, Vanlemmens C, Kraehenbuhl S, et al. Ribavirin/interferon-α sequential treatment of recurrent hepatitis C after liver transplantation. Transpl Int 2004; 17:169-176.
52. Bizollon T, Ahmed SN, Radenne S, Chevallier M, Chevallier P, Parvaz P, et al. Long-term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence. Gut 2003; 52:283-287.
53. Bizollon T, Trepo C. Ribavirin and interferon combination for recurrent post-transplant hepatitis C: which benefit beyond 6 months? J Hepat 2002; 37:274-276.
54. Samuel D. Treatment of patients with recurrent hepatitis C after transplantation with pegylated interferon and ribavirin [Abstract]. Hepatology 2003; 34:531A.
55. Neumann U, Langrehr J, Berg T, Neuhaus P. Treatment of recurrent hepatitis C after liver transplantation with peginterferon alfa-2B and ribavirin [Abstract]. Hepatology 2003; 34:531A.
56. Mukherjee S, Rogge J, Weaver L, Schafer DF. Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation. Transplant Proc 2003; 35:3042-3044.
57. Rodriguez-Luna M, Khatib A, Sharma P, De Petris G, Williams J, Ortiz J, et al. Treatment of recurrent hepatitis C infection after liver transplantation with combination of pegylated interferon alpha 2b and ribavirin: an open-label series. Transplantation 2004; 77:190-194.
58. Neff G, O'Brien C, Cirocco R, Montalbano M, de Medina M, Ruiz P, et al. Prediction of sustained virological response in liver transplant recipients with recurrent hepatitis C virus following combination pegylated interferon alfa-2b and ribavirin therapy using tissue hepatitis C virus reverse transcriptase polymerase chain reaction testing. Liver transpl 2004; 10:595-598.
59. Ross A, Bhan A, Pascual M, Thiim M, Cosimi A, Chung R, et al. Pegylated interferon α-2b plus ribavirin in the treatment of post-liver transplant recurrent hepatitis C. Clin Transplant 2004; 18:166-173.
60. Dumortier J, Scoazec JY, Chevallier P, Boillot O. Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination. J Hepat 2004; 40:669-674.
61. Samuel D. Antiviral treatment of recurrent hepatitis C after liver transplantation: the need for a multifaceted approach. Hepatology 2005; 41:436-438.
62. Sheiner PA, Schluger LK, Emre S, Thung S, Lau J, Guy S, et al. Retransplantation for recurrent hepatitis C. Liver Transpl Surg 1997; 3:130-136.
63. Rosen HR, Martin R Hepatitis C infection in patients undergoing liver retransplantation. Transplantation 1998; 66:1612-1616.
64. Rosen HR, Madden JP, Martin P. A model to predict survival following liver retransplantation. Hepatology 1999; 29:365-370.